Prof. Sadhna Sharma
Designation : Professor & Head
Department : BIOCHEMISTRY
sharma.sadhna@pgimer.edu.in

 
 
 :: Contact Details
  Phone No.    :   7087008177
  Ext No.        :   5180
 :: Educational Qualification
  Graduation :   --
  Post Graduation :   M Sc Biochemistry
  Other Qualification.(1)      :   PhD from PGIMER Chandigarh
     
 :: Area of Interest
       Area Of Interest       :
Biochemical and molecular basis of mycobacterial infections,  Nanomedicine , Drug Delivery
     
 :: Research & Projects
      Extramural Projects       :
Research is mainly focused at the understanding of various molecular mechanisms involved in the pathogenesis of tuberculosis and its associated diseases. Development of nanotechnology based drug delivery system(s) capable of overcoming limitations of conventional therapy of  various forms of tuberculosis is being extensively studied. Association of TB with diabetes and other complications is being explored
      Departmental / P.G.I.
      Projects      		 :
  •   Targeted delivery of antitubercular drugs to the brain and their therapeutic efficacy against experimental tuberculous meningitis ( 35/7/2011-BMS) in progress
  •   Nanotechnology based drug delivery and chemotherapeutic efficacy of Phenothiazine’s against active and latent tuberculosis (35/4/2009-BMS) in progress
  •  Therapeutic implications of solid lipid nanoparticles as carriers of antitubercular drugs against experimental tuberculosis. (No.01(2019)/EMR-11) completed
  •  Nuclear targets of cAMP signaling cascade and its role in cell cycle of candida albicans.(SP/SO/D-27/2000) completed
  •  Molecular characterization of peptide deformylase of Mycobacterium tuberculosis: In Vitro and ex vivo  activities of its inhibitors against M.tuberculosis. completed
  • Novel poly-lactide–co-glycolide based oral and subcutaneous sustained release drug delivery system for treatment of tuberculosis (VI-D&P/09/2003-TT) completed
  •  Poly lactide–co-glycolide nanoparticle based oral sustained drug delivery system for MDR Tuberculosis (VII-PRDSF/18/2004/TT) completed
  • Biodistribution , pharmacokinetics and chemotherapeutic efficacy of antitubercular drugs against experimental tuberculosis in guinea pigs (CSIR ) completed

 
      Research In
      Progress      		 :
Nanodelivery of drugs against tuberculous meningitis, Proteomic changes in PBMC,s of TB and Diabetic patients, Proteomics in relation to anti tubercular drug induced liver injury. 
      Area Of
      Specialization      		 :
Tuberculosis therapeutics, Applications of nanotechnology in infectious diseases
      Member Of Professional
      Bodies      		 :
  •  Life membership Society of Biological Chemists of India
  • Life membership Association of Biological Chemists of India
  •  Member American Thoracic Society
  • Member Association for promotion of DNA fingerprinting
  • Life membership Urolithiasis Society of India

 
     
 :: Publications(In Vancouver Style) 

1sList of selected publications :

1.  Mir SA, Sharma S Cloning,expression and N-terminal formylation of ESAT-6 of Mycobacterium tuberculosisH37Rv. Protein Expr Purif. 2013 ,92(2):223-9.

2.  Sandhir R, Yadav A, Mehrotra A, Sunkaria A,Singh A, Sharma S. CurcuminNanoparticles Attenuate Neurochemical and Neurobehavioral Deficits inExperimental Model of Huntington's Disease. Neuromolecular Med. 2013 Sep 6.[Epub ahead of print]

3.   Bhansali S, Shafiq N, Pandhi P, Singh AP,Singh I, Singh PK, Sharma S,Malhotra S. Effect of a deacyl gymnemic acid on glucose homeostasis &metabolic parameters in a rat model of metabolic syndrome. Indian J Med Res.2013 Jun;137(6):1174-9.

4.    Adole PS, Singh A, Kharbanda PS, Sharma S. Phenotypic interaction ofsimultaneously administered isoniazid and phenytoin in patients withtuberculous meningitis or tuberculoma having seizures.Eur J Pharmacol. 2013 Aug15;714(1-3):157-62.

5.    Varshney S, Bhadada SK, Saikia UN, Sachdeva N,Behera A, Arya AK, Sharma S,Bhansali A, Mithal A, Rao SD. Simultaneous expression analysis of vitamin Dreceptor, calcium-sensing receptor, cyclin D1, and PTH in symptomatic primaryhyperparathyroidism in Asian Indians. Eur J Endocrinol. 2013 Jun7;169(1):109-16.

6.  Mir SA, SharmaS. Role of MHC class Ib molecule, H2-M3 in host immunity againsttuberculosis. Vaccine. 2013 Aug 20;31(37):3818-25

7.    Prakash S, Sen RK, Tripathy SK, Sen IM, Sharma RR, Sharma S. Role of interleukin-6as an early marker of fat embolism syndrome: a clinical study. Clin OrthopRelat Res. 2013 Jul;471(7):2340-6

8.    Rana A, Minz RW, Aggarwal R, Sharma S, Pasricha N, Anand S, Singh S.A comparative proteomic study of sera in paediatric systemic lupuserythematosus patients and in healthy controls using MALDI-TOF-TOF and LC MS-Apilot study. Pediatr Rheumatol Online J. 2012 Aug 17;10(1):24.

9.   Kumar G, SharmaS, Shafiq N, Khuller GK, Malhotra S. Optimization, in vitro-in vivoevaluation, and short-term tolerability of novel levofloxacin-loaded PLGAnanoparticle formulation. J Pharm Sci. 2012 Jun;101(6):2165-76.

10. Sharma S, Singh A. Phenothiazines as anti-tubercularagents: mechanistic insights and clinical implications. Expert Opin InvestigDrugs. 2011 Dec;20(12):1665-76.

11.  Kumar G, Malhotra S, Shafiq N, Pandhi P,Khuller GK, Sharma S. In vitrophysicochemical characterization and short term in vivo tolerability study ofethionamide loaded PLGA nanoparticles: potentially effective agent formultidrug resistant tuberculosis. J Microencapsul. 2011; 28(8):717-28.

12.  Kumar G, SharmaS, Shafiq N, Pandhi P, Khuller GK, Malhotra S. Pharmacokinetics and tissuedistribution studies of orally administered nanoparticles encapsulatedethionamide used as potential drug delivery system in management of multi-drugresistant tuberculosis. Drug Deliv. 2011 Jan;18(1):65-71

13.  Sharma A, Khuller GK, Kanwar AJ, Sharma S. Therapeutic potential ofpeptide deformylase inhibitors against experimental tuberculosis. J Infect.2010 Jun;60(6):498-501

14.  Das PP, Malhotra S, Chakrabarti S, Sharma S. Elevated total cholesterol inseverely depressed patients: role in cardiovascular risk? World J BiolPsychiatry. 2010 Mar;11(2 Pt 2):321-8

15.  Ahmad Z, Pandey R, Sharma S, Khuller GK. Alginate nanoparticles as antituberculosisdrug carriers: formulation development, pharmacokinetics and therapeuticpotential. Indian J Chest Dis Allied Sci. 2006 Jul-Sep; 48(3):171-6.

16.  Sharma A, Khuller GK, Sharma S (2009) Peptide deformylase-a promising therapeutic target fortuberculosis and antibacterial drug discovery. Expert Opin Ther Targets. 13(7):753-65. 

17.  Sharma A, Sharma S, Khuller GK, Kanwar AJ (2009) In vitro and ex vivo activity of peptidedeformylase inhibitors against Mycobacterium tuberculosis H37Rv. Int JAntimicrob Agents.34(3):226-30.

18.  Ahmad Z, Pandey R, Sharma S, Khuller GK. Novel chemotherapy fortuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loadedPLG nanoparticles. Int J Antimicrob Agents. 2008 Feb; 31(2):142-6.

19.  Singh A, Dhillon NK, Sharma S, Khuller GK. Identification andpurification of CREB like protein in Candida albicans. Mol Cell Biochem. 2008Jan; 308(1-2):237-45.

20.  Zahoor A, Sharma S and Khuller GK (2007): Chemotherapeutic evaluation of    alginate nanoparticle-encapsulated azoleantifungal and antitubercular drug against murine tuberculosis. Nanomedicine,3: 239-243.

21.  Singh A, Sharma S and Khuller GK (2007): cAMP regulates vegetative growth and cell cycle in Candidaalbicans. Molecular and Cellular Biochemistry 304: 331-341.

22.  Rajesh Pandey, Sadhna Sharma and G.K. Khuller (2006) Chemotherapeutic efficacy of nanoparticleencapsulated antitubercular drugs. Drug Delivery 13(4):287-94.

23.   Zahoor A., Pandey R., Sharma S., & Khuller G.K(2006). Alginate nanoparticles as antitubercular drug carriers: formulationdevelopment, pharmacokinetics and therapeutic potential Indian Journal of Chestdiseases and Allied Sciences (48,171-176).

24.  Pandey R, Sadhna Sharma and G.K. Khuller. (2006). Oral poly-(lactide-co-gylcolide) nanoparticle basedantituberculosis drug delivery: Toxicological and chemotherapeuticimplications. Indian J Exp Biol. 44,459-467.

25.  Zahoor A., Pandey R, Sadhna Sharma and G.K. Khuller (2006). The potential of azole     antifungals against latent/ persistent tuberculosis. FEMS Microbiol Lett258, 200-203.

26.  Zahoor A., R. Pandey, S.Sharma & G.K. Khuller (2006)Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugsencapsulated in alginate nanoparticles at two doses. Int J Antimicrob Agents27, 420-427.                                            

27.  Zahoor A., Pandey R., Sharma S., & Khuller G.K. (2006).  Evaluation of antitubercular drug loaded alginatenanoparticles against experimentaltuberculosis. Nanoscience 1, 81-85.

28.   Zahoor A.,Sadhna Sharma and G.K. Khuller (2005).In vitro and ex vivo antimycobacterial potential of azole drugs againstM. tuberculosis H37RV. FEMS Microbiol Lett. 251:19-22.

29.  Rajesh Pandey, Sadhna  Sharma and G.K. Khuller (2005)Oral solid lipid nanoparticle based antitubercular chemotherapy. Tuberculosis85, 415-420.

30.  Christine M. Johnson, Rajesh Pandey, Sadhna Sharma, G.K. Khuller, Randall. J. Basaraba, Ian M. Orme, andAnne J. Lenaerts (2005) Oral therapy using nanoparticle encapsulatedantituberculosis drugs in guinea pigs infected with Mycobacteriumtuberculosis. Antimicrob. Agents Chemotherapy . 49, 4335-38.

31.  Zahoor A, Sadhna Sharma and G.K. Khuller (2005) Inhalablealginate nanoparticles as antitubercular drug carriers against experimentaltuberculosis. Int. J. Antimicrob Agents 26, 298-303.

32.  Rajesh Pandey, Zahoor Ahmed, Sadhna Sharma and G.K. Khuller (2005)Nano-encapsulation of azole antifungals: potential applications to improve oraldrug delivery. Int. J. Pharm. 301, 268-76.1

33.  G.K. Khuller, Manisha Kapoor and Sadhna Sharma (2004). Liposome technology for drug delivery againstmycobacterial infections. Curr. Pharm. Desig. 10, 3263-3274.

34.  Rajesh Pandey, Sadhna Sharma and G.K. Khuller (2004). Nebulization of liposome encapsulatedantitubercular drugs in guinea pigs. Int. J. Antimicrob. Agents 24, 93-94.

35.  Rajesh Pandey, Sadhna Sharmaand G.K. Khuller (2004). Lung specific stealth liposomes as antituberculardrug carriers in guinea pigs. Ind. J. Expt. Biol. 42, 562-566.

36.  Rajesh Pandey, Sadhna Sharma and G.K. Khuller (2004). Liposomes based antitubercular drug therapyin a guinea pig model of tuberculosis. Int. J. Antimicrob. Agents 23, 414-415.

37.  Anjali Sharma, Rajesh Pandey, Sadhna Sharma and G.K. Khuller (2004). Chemotherapeutic efficacy of poly(DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs atsub-therapeutic dose against experimental tuberculosis. Int. J. Antimicrob.Agents 24, 599-604.

38.  Anjali Sharma, Sadhna Sharma and G.K. Khuller (2004) Lectin functionalized poly(lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drugcarriers for treatment of tuberculosis. J. Antimicrob. Chemother. 54, 761-766.

39.  Navneet K. Dhillon, Sadhna Sharma and G.K. Khuller (2003) Influence of W-7, a calmodulin antagonist onphospholipids biosynthesis in Candida albicans. Lett. Appl. Microbiol. 36,382-386.

40.  Navneet K. Dhillon, Sadhna Sharma and G.K. Khuller (2003) Biochemical characterization ofCa2+/Calmodulin dependent protein kinase from Candida albicans.   Molecular and Cellular Biochem. 252,183-191.

41.  Navneet K Dhillon, Sadhna Sharma and G.K. Khuller (2003) Signalling through protein kinases andtranscriptional regulators in Candida albicans. CRC Reviews in Microbiol. 29,259-275.

42.  Qurrat-ul-Ain, Sadhna Sharma, G.K. Khuller and S.K. Garg (2003) Alginate based oral drug deliverysystem for tuberculosis: Pharmacokinetics and therapeutic effects. J.  Antimicrob. Chemother. 51, 931-938.

43.  Rajesh Pandey, Anjali Sharma, Zahoor A, Sadhna Sharma, G.K. Khuller & B. Prasad (2003) Poly(DL-lactide-co-glycolide) nanoparticle based inhalable sustained drug deliverysystem for experimental tuberculosis. J. Antimicrob. Chemother.  52, 981-986.

44.  Rajesh Pandey, Zahoor Ahmed, Sadhna Sharma and G.K. Khuller (2003) Nanoparticle encapsulated antituberculardrugs as a potential oral drug delivery system against murine tuberculosis.Tuberculosis 83, 373-378.

45.  Qurat-ul-Ain, Sadhna Sharma and G. K. Khuller (2003) Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampicin andpyrazinamide against experimental tuberculosis. Antimicrob. Agents andChemother. 47, 3005-3007.

46.  Sumeet Labana, Rajesh Pandey, SadhnaSharma and G. K. Khuller (2002). Chemotherapeutic activity of once weeklyadministered drugs (Isoniazid & Rifampicin) encapsulated in liposomesagainst murine tuberculosis. Int. J Antimicrob. Agents 20, 301-304.

47.  Qurrat-ul-Ain, Sadhna Sharma, S.K. Garg and G.K. Khuller (2002). Role of Poly(DL-lactide-co-glycolide) in development of sustained oral delivery system forantitubercular drug(s). Int. J. Pharm. 239, 34-46.

48.  S. Sharma, Hardeep Kaur and G.K. Khuller (2001) Cell cycle effects of phenothiazine’s:trifluoperazine and chlorpromazine in Candida albicans. FEMS Mircobiol. Lett.199, 185-190.

49.  E. Haq, Sadhna Sharma and G.K. Khuller (2001) Purification of diacylglycerol kinase from Microsporumgypseum and its phosphorylation by catalytic subunit of protein kinase A.Arch.  Biochem. Biophys. 392, 219-225.